NASDAQ$OGI
Organigram Global Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Organigram Q2 fiscal net revenue hits record $65.6M (+74%) on Motif acquisition
Organigram Global Inc. reported record second-quarter fiscal 2025 results for the period ended March 31, 2025, with gross revenue of $102.8 million and net revenue of $65.6 million, up 79% and 74% year-over-year respectively. The quarter includes a full three months of Motif Labs following the December 2024 acquisition. International revenue surged 177% to $6.1 million. Adjusted gross margin was 33% ($21.9 million) and adjusted EBITDA rose to $4.9 million from a $(1.0) million loss a year ago. Net income was $42.5 million, primarily from fair value gains on BAT top-up-rights and financial instruments rather than core operations. Organigram raised expected Motif cost synergies to approximately $15 million annually from $10 million and held cash of $83.4 million with negligible debt. The company maintained #1 Canadian market share in vapes, pre-rolls and several other categories.
- Record net revenue of $65.6 million (+74% YoY) and gross revenue of $102.8 million (+79%) driven by Motif and organic growth.
- Adjusted EBITDA of $4.9 million swung positive from $(1.0) million; adjusted gross margin held at 33%.
- Net income of $42.5 million reflected fair value gains on BAT instruments, not underlying cannabis operations alone.
- International sales of $6.1 million (+177%) and Motif synergy target raised to ~$15 million annually.
- Cash position of $83.4 million with negligible debt; #1 Canadian market share maintained across key categories.
Headline financials
Revenue & EPS history
Organigram · Revenue · Quarterly
$65.6M
Revenue by segment
Organigram · $6.1M total across 1 segment · Q1 2025
- International$6.1M—100.0%
Forward guidance
Management expects international sales to increase in the second half of fiscal 2025 and adjusted gross margins to improve as Motif synergies are realized, with seasonally stronger back-half months ahead.
Tailwinds
- Record revenue scale with Motif integration progressing ahead of synergy plan
- Strong market share leadership in Canadian cannabis
- Sanity Group and Collective Project expand international and U.S. beverage footprint
Headwinds
- Net income heavily influenced by non-operating fair value gains
- SG&A of $22.5 million reflects growth investments and Motif consolidation costs
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.5%
Avg return
Earnings day
+4.5%
Avg return
5 days after
+0.3%
Avg return
30 days after
29%
7 / 24 earnings
Positive
+40.8%
Q1 2020
Best reaction
-16.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -3.7% | -19.1% | -17.6% | |
| Q4 2025 | +8.5% | +11.7% | -11.7% | |
| Q2 2025 | +8.7% | +15.3% | +24.6% | |
| Q1 2025 | -16.8% | +15.3% | +24.6% | |
| Q4 2024 | -9.3% | -1.9% | -3.7% | |
| Q2 2024 | +4.9% | +43.7% | +27.8% | |
| Q1 2024 | -13.1% | +9.8% | -15.2% | |
| Q4 2023 | -6.9% | -3.8% | +28.2% | |
| Q3 2023 | -15.2% | -22.3% | -27.7% | |
| Q2 2023 | -13.0% | -19.4% | -28.2% | |
| Q1 2023 | +19.3% | +17.7% | +1.4% | |
| Q4 2022 | +0.0% | +19.0% | -29.0% | |
| Q3 2022 | -6.0% | +0.0% | +9.3% | |
| Q2 2022 | +21.5% | +16.8% | -22.8% | |
| Q1 2022 | -1.2% | -5.2% | -4.0% | |
| Q3 2021 | -0.4% | -4.9% | +1.1% | |
| Q2 2021 | -6.1% | -9.0% | -12.3% | |
| Q1 2021 | -6.8% | +1.7% | +107.3% | |
| Q4 2020 | -3.8% | +9.0% | +3.0% | |
| Q3 2020 | -9.9% | -11.8% | -12.5% | |
| Q2 2020 | -13.3% | -12.2% | -30.4% | |
| Q1 2020 | +40.8% | +46.2% | +7.6% | |
| Q4 2019 | -3.8% | +1.9% | -4.9% | |
| Q3 2019 | +13.4% | +8.6% | -7.9% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro